NIW Success Story: A Professional Specializing In New Drug Development

I am sharing a successful NIW (National Interest Waiver) case for a professional specializing in new drug development.

The applicant is a Chinese national who completed both a master's and a Ph.D. in biological sciences in the United States.

As for publications, the applicant had only their master's thesis and doctoral dissertation, each cited fewer than four times.
There were no additional awards or notable achievements to highlight.

Despite this, the applicant was able to achieve a successful outcome.

This success was largely due to the applicant’s active involvement in a new drug development project, where they played a key role in the successful launch of the product in the Chinese market.

Compared to a previous case I introduced involving a new drug development specialist from a major Korean pharmaceutical company, there is a notable difference:
In the Korean case, the applicant had directly participated as a scientist in the drug development process.
In contrast, in this case involving a Chinese applicant, the focus was not on the scientific research itself, but rather on demonstrating strong business capabilities — including advancing clinical trials within China, negotiating contracts with hospitals conducting the trials, and managing other business-related aspects of the project.

The petition was filed on September 5, 2024. After responding to a Request for Evidence (RFE), the case was ultimately approved on April 24, 2025.

I encourage you to also read the related posts for further insights.